



The association between inhaled corticosteroid and osteoporosis and fracture

Cheng-Yi Wang¹ and Chih-Cheng Lai²

Affiliations: ¹Dept of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. ²Dept of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan.

Correspondence: Chih-Cheng Lai, Dept of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 71051, Taiwan. E-mail: dtmed141@gmail.com

 @ERSpublications

More analysis is needed to assess the impact of inhaled corticosteroid on osteoporosis
<https://bit.ly/3u7qzpg>

Cite this article as: Wang C-Y, Lai C-C. The association between inhaled corticosteroid and osteoporosis and fracture. *Eur Respir J* 2021; 57: 2100216 [<https://doi.org/10.1183/13993003.00216-2021>].

This single-page version can be shared freely online.

To the Editor:

We read with great interest the study investigating the association between inhaled corticosteroid (ICS) and the risk of osteoporosis and fracture among COPD patients [1]. Multivariate analysis in this study demonstrated a significant dose–effect relationship between ICS and the risk of osteoporosis-related events. Compared to non-ICS users, high-dose ICS treatment was significantly associated with any osteoporosis-related event (risk ratio 1.52, 95% CI 1.24–1.62; while the corresponding estimate for low-dose ICS was 1.27, 95% CI 1.13–1.56) [1]. Overall, it is a well-designed study; however, we have one major and two minor concerns about the findings of this study.